A 52-week efficacy and safety non-inferiority study of fluticasone propionate/salmeterol 250/50 mcg BID [twice daily] delivered by dry powder inhaler (Diskus) versus mometasone furoate/formoterol fumarate 200/10 mcg BID delivered by pressurized metered-dose inhaler in persistent asthmatics previously treated with medium doses of inhaled glucocorticosteroids.

Trial Profile

A 52-week efficacy and safety non-inferiority study of fluticasone propionate/salmeterol 250/50 mcg BID [twice daily] delivered by dry powder inhaler (Diskus) versus mometasone furoate/formoterol fumarate 200/10 mcg BID delivered by pressurized metered-dose inhaler in persistent asthmatics previously treated with medium doses of inhaled glucocorticosteroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Mometasone/formoterol (Primary) ; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Oct 2012 This trial has been discontinued in Finland, Estonia, Lithuanina, Latvia, Czech Republic, Germany and Netherlands as reported by European Clinical Trials Database.
    • 29 Jan 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top